Therefore, therapeutic strategies that directly or indirectly elevate O-GlcNAc levels through HBP-associated O-GlcNAc signaling are being developed in experimental models of myocardial or cerebral ischemia, such as specific OGA inhibitor thiamet-G or glucosamine [29,30]. The gene discussed is OGA; the disease is brain ischemia.